← All indications
Leukemia, Monocytic, Acute
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.
Drugs by status
Phase 3 trials (25)
- cladribine
- decitabine
- tioguanine
- urea
- sorafenib
- busulfan
- clofarabine
- naltrexone
- aldesleukin
- idarubicin
- Filgrastim
- caspofungin
- zarnestra
- allogeneic hematopoietic stem cells
- cyclosporine
- cyclophosphamide
- daunorubicin
- fluconazole
- fludarabine
- etoposide
- sargramostim
- cytarabine
- asparaginase
- mitoxantrone
- autologous hematopoietic stem cells
Phase 2 trials (33)
- azacitidine
- vitamin d3
- methylprednisolone
- venetoclax
- lenalidomide
- trisalicylate choline
- cilengitide
- eltrombopag
- entinostat
- gemtuzumab ozogamicin
- tacrolimus
- ixazomib
- mk-8776
- msk-2206
- vitamin c
- omacetaxine
- pravastatin
- carboplatin
- ruxolitinib
- sirolimus
- arsenic trioxide
- mycophenolate
- bevacizumab
- allogeneic lymphocytes
- topotecan
- Anti-thymocyte Globulin (Rabbit)
- bortezomib
- vorinostat
- autologous umbilical cord blood
- thiotepa
- +3 more
Phase 1 trials (17)
Other trials (2)
Organizations
Organization Involved with Phase 3 Indications (4)
Organization Involved with Phase 2 Indications (15)
- Teva
- Case Western Reserve University
- Cornell University
- ECOG-ACRIN Cancer Research Group
- University of Washington
- Johns Hopkins University
- Rutgers University
- Southwest Oncology Group
- Stanford University
- University of South Florida
- Mayo Clinic
- Technion University
- University of Texas at Houston
- State University of New York, Buffalo
- Yeshiva University
Organization Involved with Phase 1 Indications (12)
Organization Involved with Other Experimental Indications (2)